MA
LGND icon

Montag & Associates’s Ligand Pharmaceuticals LGND Stock Holding History

Montag & Associates’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6
Closed -$1.06K – 1070
2025
Q3 		$1.06K Buy
+6
New +$892 ﹤0.01% 1009

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Montag & Associates's LGND Position: Q4 2025 in Review

Montag & Associates sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 6 shares — an estimated $1.06K sold.

Montag & Associates first reported a position in LGND in Q3 2025 and held it in 1 quarter. The position peaked at $1.06K in Q3 2025. 350 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Montag & Associates reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Montag & Associates sold 6 Ligand Pharmaceuticals shares in Q4 2025, an estimated $1.06K.
  • Montag & Associates first reported a position in Ligand Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Montag & Associates's Ligand Pharmaceuticals position peaked at $1.06K in Q3 2025.
  • 350 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.